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E. coli bacteremia in comparison to K.
pneumoniae bacteremia: influence of
pathogen species and ESBL production on
7-day mortality
R. Leistner1,2*, A. Bloch3, P. Gastmeier1,2 and F. Schwab1,2
Abstract
In a previous study, we demonstrated prolonged length of hospital stay in cases of extended-spectrum beta-lactamase
(ESBL)-positive K. pneumoniae bacteremia compared to bacteremia cases due to E. coli (ESBL-positive and –negative)
and ESBL-negative K. pneumoniae. The overall mortality was significantly higher in bacteremia cases resulting from
ESBL-positive pathogens but also in K. pneumoniae cases disregarding ESBL-production. In order to examine whether
pathogen species rather than multidrug resistance might affect mortality risk, we reanalyzed our dataset that includes
1.851 cases of bacteremia.
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Background
The incidence of infections associated with multidrug-
resistant Gram-negative organisms like extended-
spectrum beta-lactamase producing Enterobacteriaceae
(ESBL-E) is growing in Germany [1]. These infections,
according to reports, result in increased mortality and
an elevated financial burden for hospitals and health
care systems [2]. In 2014, we published the results of a
study on the costs of bloodstream infections (BSI) with
ESBL-E and length of resulting hospital stays [3]. Our
data showed that in particular K. pneumoniae was re-
lated to prolonged length of stays and increased hospital
costs regardless the detection of ESBL production. We
furthermore observed a significantly increased overall
mortality associated with ESBL-positive pathogens
(25.0 % vs. 19.0 %, p-value = 0.028). However, this differ-
ence in mortality was also observed in K. pneumoniae
cases compared to E. coli cases without considering
ESBL-production (25.0 % vs. 18.5 %, p = 0.006). This
observation posed the question whether the pathogen
species or multidrug resistance had a greater influence
on the mortality rate.
Methods
We reanalyzed the dataset to examine risk factors for mor-
tality including pathogen species and ESBL production. All
definitions remained the same from the previous publica-
tion with the exception of mortality rate. In order to detect
mortality rates attributable to the bloodstream infection
(BSI-attributable mortality), we focused on the 7-day mor-
tality rate after BSI onset. All other definitions were follow-
ing the original publication. The median and the
interquartile range (IQR) were calculated for continuous
parameters, numbers and percentage were calculated for
binary parameters. Differences between deceased patients
and those who survived were tested using the Wilcoxon
rank sum test for continuous variables and the Chi square
test for binary variables. A p-value <0.05 was considered
statistically significant. In the multivariable analysis, Cox-
proportional hazard regression analysis was performed to
investigate the risk factors for mortality ≤7 days after BSI
onset (BSI-attributable mortality). We calculated adjusted
hazard ratios (HR) for pathogen species and ESBL-
positivity. Model building strategy was step-wise forward
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with a p-value < .05 for including a variable in the model.
All parameters with a p-value <0.1 in the univariable ana-
lysis were considered in the multivariable analysis, and the
interaction between pathogen species and ESBL-positivity
were included in all multivariable models. Underlying
comorbidities were assessed as in the original publica-
tion. In order to enable a comparison between the
risk factors for BSI-attributable mortality (7-day mor-
tality) and in-hospital mortality, the analysis was re-
peated for the latter using the same parameters and
statistical method. All analyses were performed using
SPSS (IBM SPSS statistics, Somer, NY, USA) and SAS
(SAS Institute, Cary, NC, USA).
Results
Overall 8.7 % (n = 161) of the patients were deceased
within seven days of developing a bloodstream infec-
tion whereas n = 205 (11.1 %) patients died at a later
point in time during their hospital stay (Table 1). In
the univariable analysis, patients who died within the
7 days after BSI onset were significantly older com-
pared to the 7-day survivors. However, this was not
observed concerning overall in-hospital mortality.
With respect to the 7-day mortality, there was no
statistical significant difference observed concerning
ESBL-production or pathogen species. Furthermore,
the following parameter showed significantly increased
risk for overall in-hospital mortality but not for 7-day
mortality: polymicrobial BSI, male sex, hospital onset,
cerebrovascular disease, lung disease and cancer/im-
munological disease.
In the multivariable analysis, independently associ-
ated factors with 7-day mortality were renal disease,
liver disease, cancer /immunological disease and heart
disease (Table 2). No effect was observed concerning
neither pathogen species nor ESBL-production. For
overall in-hospital mortality, a similar risk profile
could be observed concerning underlying diseases.
Table 1 Univariate analysis of 7 days mortality in patients with extended-spectrum beta-lactamase (ESBL)-positive or -negative E. coli
and K. pneumoniae bloodstream infection (during hospitalization)
Parameter Survived until
7 days after BSI
Died within










Number (%) Number (%) Number (%) Number (%)
Patients 1.690 (100 %) 161 (100 %) 8.7 % 1485 (100 %) 366 (100 %) 19.8 %
K. pneumoniae 319 (18.9 %) 33 (20.5 %) 9.4 % 0.616 264 (17.8 %) 88 (24.0 %) 25.0 % 0.006
E. coli 1371 (81.1 %) 128 (79.5 %) 8.5 % 1221 (82.2 %) 278 (76.0 %) 18.5 %
ESBL-positive 219 (13.0 %) 25 (15.5 %) 10.2 % 0.357 183 (12.3 %) 61 (16.7 %) 25.0 % 0.028
Hospital mortality 205 (12.1 %) 161 (100.0 %) 44.0 % <0.001 - 366 (100.0 %) 100.0 % n.a.
Polymicrobial 198 (11.7 %) 27 (16.8 %) 12.0 % 0.061* 160 (10.8 %) 65 (17.8 %) 28.9 % <0.001*
Age (years)a 65 (52–73)a 67 (57–76)a n.a. 0.019* 65 (52–73)a 66 (54–74)a n.a. 0.134*
Male 929 (55.0 %) 93 (57.8 %) 9.1 % 0.496 799 (53.8 %) 223 (60.9 %) 21.8 % 0.014
Hospital onset 746 (44.1 %) 84 (52.2 %) 10.1 % 0.050* 612 (41.2 %) 218 (59.6 %) 26.3 % <0.001*
ICU stay 1.072 (63.4 %) 125 (77.6 %) 10.4 % <0.001* 896 (60.3 %) 301 (82.2 %) 25.1 % <0.001*
Charlson comorbidity indexa 5 (3–8)a 8 (6–10)a n.a. <0.001 5 (3–8)a 8 (6–10)a n.a. <0.001
Heart disease 275 (16.3 %) 47 (29.2 %) 14.6 % <0.001* 215 (14.5 %) 107 (29.2 %) 33.2 % <0.001*
Cerebrovascular disease 243 (14.4 %) 31 (19.3 %) 11.3 % 0.096* 202 (13.6 %) 72 (19.7 %) 26.3 % 0.003*
Neurologic disease 123 (7.3 %) 11 (6.8 %) 8.2 % 0.835 112 (7.5 %) 22 (6.0 %) 16.4 % 0.311
Lung disease 218 (12.9 %) 24 (14.9 %) 9.9 % 0.470 181 (12.2 %) 61 (16.7 %) 25.2 % 0.023
Gastrointestinal disease 53 (3.1 %) 12 (7.5 %) 18.5 % 0.004* 36 (2.4 %) 29 (7.9 %) 44.6 % <0.001*
Rheumatic disease 50 (3.0 %) 2 (1.2 %) 3.8 % 0.208 44 (3.0 %) 8 (2.2 %) 15.4 % 0.420
Liver disease 258 (15.3 %) 53 (32.9 %) 17.0 % <0.001* 180 (12.1 %) 131 (35.8 %) 42.1 % <0.001*
Diabetes 422 (25.0 %) 48 (29.8 %) 10.2 % 0.177 366 (24.6 %) 104 (28.4 %) 22.1 % 0.138
Renal disease 711 (42.1 %) 115 (71.4 %) 13.9 % <0.001* 565 (38.0 %) 261 (71.3 %) 31.6 % <0.001*
Cancer/immunological disease 672 (39.8 %) 75 (46.6 %) 10.0 % 0.092* 571 (38.5 %) 176 (48.1 %) 23.6 % 0.001*
BSI bloodstream infection, LOS length of stay, N.a. not applicable
* Included in the multivariable Cox-proportional hazard regression
a Continuous parameter displayed as median (interquartile range)
P-values <0.05 were considered statistically significant
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Here, BSI with ESBL-negative K. pneumoniae was
found to be an independent risk factor for overall in-
hospital mortality.
Discussion
In earlier studies, ESBL-positive pathogens causing in-
fections were associated with increased mortality [2].
However, recent studies have cast doubt on this gen-
eral assumption and showed a lack of sufficiently con-
trolled studies especially with respect to antimicrobial
treatment [4, 5]. Unfortunately, we do not have suffi-
cient data on antimicrobial treatment and are unable
to examine this assumption. Especially carbapenem re-
sistance poses a serious threat, as carbapenems are the
most important reserve substances for these infections
[6]. However, our cohort was comprised of only two
cases resulting from carbapenem-resistant organisms.
In the original publication, K. pneumoniae cases were
associated with a significantly higher comorbidity index
(6 vs. 5, p = 0.001). K. pneumoniae BSIs were more often
associated with the detection of other organisms in the
same blood culture (24.4 % vs. 9.9 %, p ≤ 0.001) and they
occurred later than the respective E. coli BSIs (hospital
day 6 vs. 1, p ≤ 0.001). These observations indicate epi-
demiological and pathophysiological differences between
both groups that we do not yet entirely understand.
In the analysis at hand, we observed severe comorbidi-
ties, like renal disease, liver disease or cancer to be the
only independently associated risk factors for BSI-
attributable mortality. In contrast, ESBL-negative K. pneu-
moniae (in addition to comorbidities) was independently
associated with in-hospital mortality. We see this as the
result of an unmeasured confounder that is associated
with increased risk of mortality in the aftermath of sur-
vival from a K. pneumoniae BSI.
This analysis has limitations. Our data lacks information
on antimicrobial therapy, which could provide further
information. However, the patients were treated following
current sepsis guidelines. The guidelines do not differentiate
between K. pneumoniae and E. coli and therefore render a
systematical therapeutic difference unlikely. Data on source
of BSI and on the severity of disease (e.g. sepsis, septic
shock) were not sufficiently available. Therefore, we could
not adjust for the effect of these potential confounders.
Conclusions
ESBL-E BSI-attributable mortality was influenced neither
by pathogen species nor by ESBL-production. However,
we observed epidemiological differences between patients
infected with K. pneumoniae or E.coli that lead to an in-
creased in-hospital mortality, not attributable to the BSI
episode. Both pathogens are the most commonly found
representatives of ESBL-producing bacteria in clinical iso-
lates. Hence, it is of paramount importance to understand
the factors that determine the course of infection and the
overall outcome. Thus, further well-designed studies of
epidemiological and pathophysiological differences be-
tween K. pneumoniae and E. coli -infections are necessary.
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Table 2 Multivariable Cox-proportional hazard regression of risk factors for 7-day mortality and hospital mortality after BSI with
ESBL-positive or -negative E. coli and K. pneumoniae
Parameter Parameter/ category 7-days mortality (stepwise) In-hospital mortalitya
HR CI95 P-value HR CI95 P-value
Interaction effect between pathogen
species and ESBL-production
E. coli ESBL-negative 1 = Reference 0.947 1 = Reference 0.084
E. coli ESBL-positive 1.16 0.70–1.90 0.571 1.22 0.88–1.68 0.228
K. pneumoniae ESBL-negative 0.98 0.64–1.50 0.926 1.39 1.07–1.82 0.015
K. pneumoniae ESBL-positive 1.05 0.49–2.27 0.894 1.01 0.60–1.67 0.983
Comorbidities Heart disease 1.55 1.09–2.21 0.014 1.23 0.97–1.56 0.087
Liver disease 1.96 1.40–2.74 <0.001 1.85 1.48–2.30 <0.001
Renal disease 2.86 1.99–4.10 <0.001 2.32 1.82–2.95 <0.001
Cancer/ immunological disease 1.66 1.21–2.28 0.002 1.58 1.28–1.95 <0.001
ESBL extended-spectrum beta-lactamase, HR hazard ratio, CI95 95 % confidence interval, N.s. not significant
aAnalyzing the same parameters as in 7-days mortality
P-values <0.05 were considered statistically significant
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